Evolus, Inc. (EOLS) Financials

EOLS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 248.0 million 278.9 million
March 31, 2026 220.6 million 249.4 million
Dec. 31, 2025 225.9 million 249.0 million
Sept. 30, 2025 219.0 million 247.8 million

EOLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -2.4 million 5.6 million
March 31, 2026 -11.6 million 5.1 million
Dec. 31, 2025 10.7 million 5.1 million
Sept. 30, 2025 -16.8 million 5.1 million

EOLS Net Income

No data available :(

EOLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 45.2 million 156.7 million 8.1 million
March 31, 2026 49.8 million 156.4 million 8.5 million
Dec. 31, 2025 53.8 million 146.1 million 8.9 million
Sept. 30, 2025 43.5 million 145.8 million 6.6 million

EOLS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 65.9 million
March 31, 2026 65.2 million
Dec. 31, 2025 64.5 million
Sept. 30, 2025 64.7 million

EOLS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 1.2 million 1.9 million 57.1 million -
March 31, 2026 1.7 million 2.2 million 52.0 million -
Dec. 31, 2025 2.2 million 3.5 million 54.7 million -
Sept. 30, 2025 2.2 million 2.0 million 52.8 million -

EOLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 84.1 million 26.9 million
March 31, 2026 73.1 million 25.8 million
Dec. 31, 2025 90.3 million 31.0 million
Sept. 30, 2025 69.0 million 23.1 million

EOLS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

EOLS

Price: $7.61

52 week price:
3.86
9.31

Earnings Per Share: -0.53 USD

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 16622

Market Capitalization: 470.2 million

Links: